To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves AbbVie’s Mavyret for HCV

FDA approved Mavyret glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV genotypes 1-6 infection in previously untreated adults

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE